Advertisement

Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?

  • Fabián PitoiaEmail author
  • Osvaldo J. Degrossi
  • Hugo Niepomniszcze
Letter to the Editor

Keywords

Thyroid Carcinoma Differentiate Thyroid Carcinoma Thyroid Remnant Euthyroid Patient Thyroid Hormone Withdrawal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Luster M, Sherman SI, Skarulis MC et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003; 30:1371–1377.CrossRefPubMedGoogle Scholar
  2. 2.
    Pacini F, Molinaro E, Castagna MG et al. Ablation of thyroid residues with 30 mCi131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87:4063–4068.Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Fabián Pitoia
    • 1
    Email author
  • Osvaldo J. Degrossi
    • 2
  • Hugo Niepomniszcze
    • 1
  1. 1.División Endocrinología, Hospital de Clínicas José de San MartínUniversity of Buenos AiresArgentina
  2. 2.Instituto Argentino de Diagnóstico y TratamientoBuenos AiresArgentina

Personalised recommendations